v3.24.2.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Total revenue $ 57,597 $ 57,021 $ 112,189 $ 119,838
Total cost of revenue 32,407 32,288 65,224 68,033
Gross margin 25,190 24,733 46,965 51,805
Operating costs and expenses:        
Selling, general and administrative 35,963 38,802 74,267 72,043
Engineering and development 4,646 4,263 9,398 8,139
Impairment loss 63,809   63,809  
Total operating costs and expenses 104,418 43,065 147,474 80,182
Loss from operations (79,228) (18,332) (100,509) (28,377)
Other income (expense):        
Investment income 2,809 2,647 5,409 5,114
Interest expense (1,245) (1,331) (2,583) (2,840)
Gain on extinguishment of debt, net 1,179   1,179  
Other income (expense), net (1,121) (704) 218 3,301
Total other income, net 1,622 612 4,223 5,575
Loss before provision for income taxes (77,606) (17,720) (96,286) (22,802)
Provision for income taxes (383) (635) (598) (1,127)
Net loss (77,989) (18,355) (96,884) (23,929)
Paid-in-kind dividend on Series C convertible preferred stock (2,000) (2,000) (4,000) (4,000)
Net loss attributable to common stockholders $ (79,989) $ (20,355) $ (100,884) $ (27,929)
Net loss per share - basic (in dollar per share) $ (1.62) $ (0.42) $ (2.05) $ (0.58)
Net loss per share - diluted (in dollar per share) $ (1.62) $ (0.42) $ (2.05) $ (0.58)
Weighted average shares outstanding - basic (in shares) 49,345,644 48,709,384 49,182,830 48,536,901
Weighted average shares outstanding - diluted (in shares) 49,345,644 48,709,384 49,182,830 48,536,901
Life Sciences Services        
Total revenue $ 38,040 $ 35,204 $ 74,826 $ 71,040
Total cost of revenue 21,105 20,008 42,707 39,084
Life Sciences Products        
Total revenue 19,557 21,817 37,363 48,798
Total cost of revenue $ 11,302 $ 12,280 $ 22,517 $ 28,949

Source